Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Work In Process (2021 - 2025)

Dr Reddys Laboratories has reported Work In Process over the past 5 years, most recently at $190.8 million for Q1 2025.

  • For Q1 2025, Work In Process rose 11.43% year-over-year to $190.8 million; the TTM value through Mar 2025 reached $190.8 million, up 11.43%, while the annual FY2025 figure was $195.5 million, 13.8% up from the prior year.
  • Work In Process for Q1 2025 was $190.8 million at Dr Reddys Laboratories, up from $171.3 million in the prior quarter.
  • Over five years, Work In Process peaked at $190.8 million in Q1 2025 and troughed at $137.3 million in Q1 2021.
  • A 5-year average of $162.6 million and a median of $171.3 million in 2024 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: rose 24.84% in 2022 and later fell 16.96% in 2023.
  • Year by year, Work In Process stood at $137.3 million in 2021, then rose by 24.84% to $171.4 million in 2022, then fell by 16.96% to $142.3 million in 2023, then increased by 20.34% to $171.3 million in 2024, then rose by 11.43% to $190.8 million in 2025.
  • Business Quant data shows Work In Process for RDY at $190.8 million in Q1 2025, $171.3 million in Q1 2024, and $142.3 million in Q1 2023.